The US FDA has cleared Bioness Inc’s L300 Go System, which according to the company is reportedly the first functional electrical stimulation device to provide 3D motion of gait events from a 3-axis gyroscope and accelerometer.
The L300 Go System, which builds upon the company’s NESS L300 Foot Drop System and NESS L300 Plus System, also features multi-channel stimulation that allows clinicians to precisely control the amount of dorsiflexion and inversion/eversion the system provides, and a mobile iOS application to track activity, set goals, and review progress over time.
The system monitors patient movement in all three kinematic planes, and deploys stimulation precisely when needed during the gait cycle. An adaptive, learning algorithm accommodates changes in gait dynamics, and a high-speed processor deploys stimulation within 10 milliseconds of detecting a valid gait event, explains the Valencia-based company in a media release.
“Technological innovations including 3D motion detection and multi-channel stimulation work together to improve treatment efficiency and promote patient mobility,” says Todd Cushman, president and CEO of Bioness, in the release. “At Bioness, we are focused on improving the lives of patients through technology and are proud to add the L300 Go into our growing portfolio of products.”
Bioness will begin the commercial release of the L300 Go during spring 2017.
[Source(s): Bioness Inc, PR Newswire]
